4.97 0.00 (0.02%)
After hours: 4:37PM EDT
|Bid||4.95 x 2200|
|Ask||5.02 x 1200|
|Day's Range||4.88 - 5.07|
|52 Week Range||3.22 - 7.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.83|
Conatus Pharmaceuticals (CNAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The San Diego-based company said it had a loss of 17 cents per share. The results matched Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was also for ...
SAN DIEGO, May 02, 2018-- Conatus Pharmaceuticals Inc., a biotechnology company focused on the development of novel medicines to treat liver disease, today announced financial results for the first quarter ...
Amicus Therapeutics (FOLD) is a global patient-focused biotechnology company engaged in developing and commercializing diverse novel treatments for patients with rare metabolic diseases. As of April 2018, of the seven analysts covering Amicus Therapeutics, three have given the stock “strong buy” ratings, three have given it “buy” ratings, and one has given it a “hold” rating. The mean rating for the stock is 1.71 with a target price of $19.93, implying an upside of almost 45% to $13.79 as of its closing on April 24.
Conatus Pharmaceuticals Inc. (CNAT) today announced the completion of enrollment in ENCORE-PH, a Phase 2b clinical trial evaluating emricasan, the company’s first-in-class, orally-active pan-caspase inhibitor. Top-line results from the ENCORE-PH clinical trial are expected in the fourth quarter of 2018. “We were pleased to complete enrollment in the ENCORE-PH clinical trial on schedule,” said David T. Hagerty, M.D., Executive Vice President of Clinical Development at Conatus.
Conatus' (CNAT) might see improvement in Q1 courtesy of its lead candidate emricasan. However, the company's portfolio is devoid of an approved product and its resulting revenues.
SAN DIEGO, April 25, 2018-- Conatus Pharmaceuticals Inc. today announced that it will report financial results for the first quarter ended March 31, 2018, after the market close on Wednesday, May 2, 2018. ...
Conatus Pharmaceuticals Inc. (CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the publication1 of results from both in vitro and in vivo studies of its pan-caspase inhibitor, IDN-7314, demonstrating reductions of hepatic tissue factor-driven coagulation. Patients with liver cirrhosis can suffer caspase-driven complications of both excessive bleeding and excessive clotting. The current studies suggest that a pan-caspase inhibitor may have the potential to reduce excessive clotting in patients with severe liver disease.
Regenxbio (RGNX) is a clinical-stage biotechnology company focused on developing gene therapy product candidates to address genetic defects. The company’s product candidate RGX-314 is designed for the treatment of wet age-related macular degeneration (or wet AMD), which is a leading cause of total and partial vision loss in the US, Europe, and Japan. The other promising product candidate in Regenxbio’s pipeline is RGX-501 for the treatment of homozygous familial hypercholesterolemia (or HoFH).
The biotech sector was in the news last week as shares of Spectrum surged on positive data from a phase II study while Incyte plunged on the failure of melanoma study.
Stock Monitor: Titan Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 11, 2018 / Active-Investors.com has just released a free research report on Conatus Pharma Inc. (NASDAQ: CNAT ). If you ...
SAN DIEGO, April 09, 2018-- Conatus Pharmaceuticals Inc., a biotechnology company focused on the development of novel medicines to treat liver disease, today announced an upcoming oral presentation reporting ...
Enanta Pharmaceuticals (ENTA) is a biotechnology company with a chemistry-driven approach. Enanta Pharmaceuticals discovered glecaprevir, a protease inhibitor for the treatment of chronic hepatitis C virus (or HCV). Enanta’s second protease inhibitor under its collaboration with AbbVie is marketed under the tradename Viekera Pak under AbbVie’s initial DAA regimens for the treatment of chronic HCV.
Acorda Therapeutics (ACOR), a biopharmaceutical company, develops therapies for neurological disorders. Of the ten analysts covering Acorda Therapeutics in April 2018, three have recommended “buy,” six have recommended “hold,” and one has recommended “sell.” Their mean rating for the stock is 2.8, and their target price is $24.78. Of the 20 analysts covering Intercept Pharmaceuticals (ICPT) in April 2018, ten have recommended “buy” or a higher rating, seven have recommended “hold,” and three have recommended “sell.” The mean rating for the stock is 2.5, and its target price is $110.91.
FibroGen (FGEN) is a biopharmaceutical company involved in the discovery and development of first-in-class therapeutics. The drug is in Phase 3 of development for the treatment of anemia in chronic kidney disease. The company has adopted a global approach to the development and commercialization of its product candidates.
Intercept Pharmaceuticals (ICPT) is a biopharmaceutical company focused on developing and commercializing novel therapeutics for the treatment of viral, progressive liver diseases utilizing its proprietary bile acid chemistry. Of the 20 analysts covering Intercept Pharmaceuticals in April 2018, ten of them have given the stock a “buy” or higher rating. Seven analysts have given it a “hold,” and three have given it a “sell.” The mean rating for the stock is 2.5 with a target price of $110.91.
Investors in Conatus Pharmaceuticals (CNAT) need to pay close attention to the stock based on moves in the options market lately.
NEW YORK, NY / ACCESSWIRE / April 6, 2018 / Shares of biotech stock Intercept headed higher on Thursday after the company announced that it had priced its upsized underwritten public offering. Shares of ...
Conatus Pharmaceuticals' (CNAT) emricasan fails to meet the primary endpoint in a phase IIb study on liver transplant patients with fibrosis or cirrhosis.
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has taken a real hit heading into the latter half of this week on some fresh trial data. The company fell more than 33% during the session on Wednesday, closing out at $4.01 a share on a substantial multiplier of its average daily volume. So what happened? As noted, the action […] The post Here’s What’s Moving Conatus And Paratek appeared first on Market Exclusive.
NEW YORK, NY / ACCESSWIRE / April 5, 2018 / After falling sharply on global trade fears in early trading Wednesday, U.S. stocks rallied to close in the green. The Dow Jones Industrial Average touched a ...
A lottery ticket, however, costs only a buck or two, while getting a biotech company wrong can hurt a lot more than that. Case in point: Conatus Pharmaceuticals (NASDAQ:CNAT) shares are diving over 25% in after-hours trading Wednesday, after the drug maker announced that POLT-HCV-SVR, the company’s exploratory Phase 2b POLT-HCV-SVR proof-of-concept clinical trial, did not meet its primary endpoint. POLT-HCV-SVR, initiated in the second quarter of 2014, in approximately 60 post-orthotopic liver transplant (POLT) recipients with liver fibrosis or cirrhosis post-transplant as a result of recurrent HCV infection who have successfully achieved a sustained viral response (SVR) following HCV antiviral therapy.
Conatus Pharmaceuticals Inc. shares dropped in the extended session after the biotech company said a clinical study of its liver disease treatment did not reach its goals. Conatus shares, which had been ...